Results 241 to 250 of about 757,323 (338)

Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in Germany

open access: yesInternational Journal of Cancer, Volume 159, Issue 9, Page 2290-2299, 1 November 2026.
Molecular tumor boards (MTB), interdisciplinary teams that use tumor genomic data to guide personalized treatment decisions, have emerged as a promising strategy in melanoma care, although their real‐world clinical impact remains uncertain. This retrospective study evaluated advanced melanoma patients to assess molecularly guided treatment ...
Glenn Geidel   +26 more
wiley   +1 more source

The FOXQ1/SSBP2 Regulatory Axis Drives Malignant Progression of Melanoma

open access: yesMolecular Carcinogenesis, Volume 65, Issue 11, Page 1459-1477, November 2026.
ABSTRACT Melanoma is a highly aggressive skin cancer with poor prognosis, often linked to excessive UV exposure. Despite advancements in immunotherapy and targeted treatments, melanoma's invasiveness and metastatic potential remain significant challenges.
Xiaoyu Zhang   +4 more
wiley   +1 more source

The role of CCND1 alterations during the progression of cutaneous malignant melanoma

open access: yesTumor Biology, 2012
L. Vízkeleti   +9 more
semanticscholar   +1 more source

Diabetes and melanoma: Impact on prognosis and healthcare costs

open access: yes
Journal of the European Academy of Dermatology and Venereology, EarlyView.
Alessandra Buja   +13 more
wiley   +1 more source

Redefining CHI3L1: Therapeutic Opportunities at the Crossroads of Immune Suppression and Disease Progression

open access: yesMedicinal Research Reviews, Volume 46, Issue 6, Page 1897-1921, November 2026.
ABSTRACT Chitinase‐3‐like‐1 (CHI3L1, also known as YKL‐40) has been recognized as a biomarker of inflammation and tissue remodeling and has now emerged as a pseudoenzymatic immune checkpoint. Recent structural, immunological, and translational studies redefine it as an active regulator of immune suppression rather than a passive disease marker. Despite
Kirti Upmanyu   +2 more
wiley   +1 more source

Comprehensive genomic profiling of mucosal melanoma reveals novel fusion transcripts and dysregulation of cell‐cycle, MAPK, and PI3K pathways

open access: yesThe Journal of Pathology, Volume 270, Issue 3, Page 380-395, November 2026.
Abstract Mucosal melanomas (MMs) are rare, aggressive cancers with poor outcomes and limited response to standard therapies. A significant knowledge gap exists regarding their genomic landscape and corresponding druggable targets. This study explores this issue through a multi‐omic analysis, including whole exome‐, RNA‐, and targeted sequencing, of ...
Matilde Monti   +21 more
wiley   +1 more source

Anaplastic cutaneous plasmacytoma in a dog

open access: yesVeterinary Record Case Reports, Volume 14, Issue 4, November 2026.
Abstract Extramedullary cutaneous plasmacytoma is an uncommon tumour in dogs and rare in cats, often linked to chronic inflammation or prolonged antigenic stimulation. It typically affects middle‐aged to older dogs, involving the head, trunk, limbs and digits.
André Castilhano Marcelino Silva   +4 more
wiley   +1 more source

Pancarpal arthrodesis with medial plate fixation following amputation of metacarpal II in a dog with extensive digital squamous cell carcinoma

open access: yesVeterinary Record Case Reports, Volume 14, Issue 4, November 2026.
Abstract A 10‐year‐old, male neutered, Scottish Terrier was referred for progressive right forelimb lameness attributed to a firm spherical mass in the location of a previous digit I amputation, performed 13‐months prior to presentation. Radiographs revealed a well‐defined expansile lytic bone and soft tissue mass obliterating metacarpal I with smooth ...
Lauren Ho, Jamie‐Leigh Thompson
wiley   +1 more source

Home - About - Disclaimer - Privacy